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 Introduction 
Vancomycin is a glycopeptide antibiotic that has been 
in clinical use for nearly 50 years to treat methicillin- 
resistant Staphylococcus aureus infections.
1 It is water 
soluble,  having  a  high  molecular  weight,  and  poorly 
absorbed after oral administration. It is well known that 
VCM,  is  very  poorly  absorbed  from  the  GI  tract, 
usually  generating  serum  concentrations  that  are 
minimal or undetectable.
2-5 VCM was very stable in the 
supernatant of intestinal mucosal homogenate and that 
its  binding  to  gastric  mucin.  VCM  exhibited  a 
secretory-oriented  manner  in  both  the  jejunum  and 
ileum. known P-glycoprotein modulators, significantly 
enhanced the serosal -to- mucosal permeation of VCM. 
It was suggested that intestinal P-glycoprotein might be 
involved in the poor absorption of VCM from rat small 
intestine as a potent barrier.
6 Nanoparticulate polymeric 
delivery systems have been investigated as a possible 
accessibility  to  increase  the  oral  drug  availability. 
Biodegradable particulate carrier systems are of interest 
as  potential  means  for  oral  delivery  to  enhance  drug 
absorption,  improve  bioavailability  and  targeting  of 
therapeutic  agents  to  specific  organ,
7-10 because  it  is  
nontoxic biodegradable polymer and well tolerated by 
the  human  body.  Eudragit  RS-100  is  a  polymer  has 
been  commonly  employed  for  the  preparation  of 
controlled-release oral pharmaceutical dosage forms.
11 
As  Eudragit  RS-100  is  insoluble  at  physiological  pH 
values, therefore it has been utilized as a good polymer 
for the preparation of pH-independent sustained-release 
formulations  of  drugs.  Various  non-biodegradable 
polymers with good biocompatibility such as Eudragit 
and  ethyl  cellulose  were  used  in  the  preparation  of 
nanospheres.
11  The  presence  of  a  polymeric  wall 
supplies  a  protection  from  the  gastrointestinal 
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Physicochemical properties 
Purpose:  The  purpose  of  this  work  was  to  preparation  of  vancomycin  (VCM) 
biodegradable nanoparticles to improve the intestinal permeability, using water-in-oil-
in-water  (W/O/W)  multiple  emulsion  method.  Methods:  The  vancomycin-loaded 
nanoparticles were created using double-emulsion solvent evaporation method. Using 
Eudragit RS100 as a coating material. The prepared nanoparticles were identifyed for 
their  micromeritic  and  crystallographic  properties,  drug  loading,  particle  size,  drug 
release,  Zeta  potential,  effective  permeability  (Peff) and  oral fractional  absorption. 
Intestinal  permeability  of  VCM  nanoparticles  was  figured  out,  in  different 
concentrations using SPIP technique in rats.  Results: Particle sizes were between 362 
and  499  nm  for  different  compositions  of  VCM-RS-100  nanoparticles.  Entrapment 
efficiency expansed between 63%-94.76%. The highest entrapment efficiency 94.76% 
was obtained when the ratio of drug to polymer was 1:3. The in vitro release studies 
were accomplished in pH 7.4. The results showed that physicochemical properties were 
impressed by drug to polymer ratio. The FT-IR, XRPD and DSC results ruled out any 
chemical  interaction  betweenthe  drug  and  RS-100.  Effective  intestinal  permeability 
values of VCM nanoparticles in concentrations of 200, 300 and 400 µg/ml were higher 
than  that  of  solutions  at  the  same  concentrations.  Oral  fractional  absorption  was 
achieved  between  0.419-0.767.    Conclusion:  Our  findings  suggest  that  RS-100 
nanoparticles  could  provide  a  delivery  system  for  VCM,  with  enhanced  intestinal 
permeability. 
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environment and may lengthen contact of nanospheres 
with the epithelium that may be enough to increase the 
bioavailability  of  certain  drugs.
12-16  In  the  present 
investigation, VCM was incorporated in Eudragit RS-
100  nanoparticles,  with  the  aim  of  ameliorating 
intestinal permeability. Loading of VCM, a hydrophilic 
antibiotic,  into  RS-100  microparticles  can  be 
problematic owing to its high hydrophilicity . The most 
used technique to encapsulate hydrophilic molecules is 
the  double  (water-in-oil-in-water,  W/O/W) 
emulsification  method,  followed  by  solvent 
extraction/evaporation.
17  Aqueous  solution  of  the 
hydrophilic  compound  is  first  emulsified  in  organic 
solution of the polymer. The primary emulsion is then 
poured into a  large volume of  water with or  without 
surfactant.  The  double  emulsion  technique  has  fairly 
good  encapsulation  efficiency  for  hydrophilic 
compounds;  however,  particle  size  is  usually  larger 
than  with  single  emulsion  technique.
18  Multiple 
emulsions of the W/O/W type are excellent candidates 
for  controlled  and  sustained  release  of  hydrophilic 
drugs due to  the existence  of a middle  oil layer  that 
accomplishes as a liquid membrane.
19 
However,  there  have  been  no  reports  on  preparing 
VCM nanoparticles using  RS-100  and assessing their 
intestinal  permeability.  One  of  the  most  used  classic 
techniques  in  the  study  of  intestinal  absorption  of 
compounds  has  been  the  single-pass  intestinal 
perfusion (SPIP) model, which provides experimental 
conditions nearer to what is encountered following oral 
administration.
12-16  SPIP  is  the  most  used  classic 
technique  employed  in  the  study  of  intestinal 
absorption  of  compounds  in  which  a  non-absorbable 
marker such as phenol red is used to adjust the water 
flux.
20 SPIP proposes a simple and relevant method of 
permeability  evaluation  and  coordinates  very  much 
with the true absorption properties in human beings.
21 
The applicability of the method is assessed by testing 
the  physiological  function  of  the  rat  intestine  during 
perfusions.  This  technique  has  lower  delicacy  to  pH 
variations and it maintains an intact blood supply to the 
intestine.
12-16 The objective of this study was improving 
intestinal permeation. It sounds alternative formulations 
are  needed  to  extend  the  time  over  which  the  VCM 
intestinal  level  remains  high  enough  and  therefore 
enhance the oral performance of this suitable antibiotic. 
Reversed-phase  high  performance  liquid 
chromatography (HPLC) is the  most credible approach 
to the assay.
22 In this study, we identified Peff and oral 
fractional absorption (Fa) of VCM in the rat intestine. 
 
Materials and Methods 
Materials 
Vanko
®  was  obtained  from  Jaberebnehyan 
Pharmaceutical  Company,  Iran.  Eudragit  RS-100  was 
purchased  from  RÖhm  Pharma  GMBh,  Weiterstadt, 
Germany.  Poly  vinyl  alcohol  (PVA)  with  molecular 
weight of 95000 Da was provided byAcros Organics, 
Geel,  Belgium.  Dichloromethane,  methanol,  glacial 
acetic  acid,  triethanolamine,  hydrochloric  acid, 
potassium chloride, acetone, sodium chloride, sodium 
hydrogen  phosphate  (dibasic),  potassium  dihydrogen 
phosphate  were  received  from  Merck,  Darmstadt, 
Germany. Dialysis bag (10,000 Da) for invitro release 
studies  was  procured  from  Biogene  (Mashhad,  Iran). 
Male Wistar rats were purchased from the animal house 
of  Tabriz  University  of  Medical  Sciences.  All  other 
reagents used were analytical grade. 
 
Preparation of nanoparticles 
VCM- Eudragit RS100 nanoparticles were prepared by 
the  W1/O/W2  modified  solvent  evaporation  method  
Using different ratios of drug to polymer (1:1, 1: 2 and 
1:  3).  Briefly,  5  ml  of  aqueous  internal  phase  was 
emulsified  for  120  s  in  20  ml  of  methylene  chloride 
(containing  100,  200  and  300  mg  Eudragit  RS-100) 
using  homogenizer  with  24000  rpm.    This  primary 
emulsion was added into 25 ml of a 0.2% PVA aqueous 
solution while stirring using a homogenizer for 3 min, 
immersed in an ice water bath, to create the water in 
oil-in-water  emulsion.  Approximately  five  ml  of  NP 
suspension  was  prepared  after  solvent  evaporation 
under reduced pressure (Evaporator, Heidolph, USA). 
Nanoparticles were separated from the bulk suspension 
by  centrifugation  (Hettich  universal  320R,  USA)  at 
21,460×g  for  20  min.  The  supernatant  was  kept  for 
drug  assay  as  described  later  and  the  precipitated 
nanoparticles were collected by filtration and washed 
with  three  portions  of  30  ml  of  water  and  were 
redispersed  in  5  ml  of  purified  water  before  freeze-
drying.  After  lyophilization,  the  dried  nanoparticles 
were resuspended in 50 ml of Phosphate buffered saline 
(PBS)12hrs  before  perfusion.  Blank  nanoparticles 
(without  drug)  were  prepared  under  the  same 
conditions without drug.
23,24 
 
Nanoparticle size  
A laser light scattering particle size analyzer (SALD-
2101,  Shimadzu,  Japan)  was  used  to  determine  the 
particle size of the drug, polymer and nanoparticulate 
formulations.  Samples  were  suspended  in  distilled 
water (nanoparticles and polymer) or acetone (drug) in 
a  10  cm  cuvette  and  stirred  continuously  during  the 
particle size analysis.  
 
Zeta potential measurement  
The zeta potential of a nanoparticle is commonly used 
to  characterise  the  surface  charge  property  of 
nanoparticles.  It  shows  the  electrical  potential  of 
particles  is  influenced  by  the  composition  of  the 
particle  and  the  medium  in  which  it  is  dispersed. 
Currently principal technique involved in zeta potential 
determination  is  laser  doppler  anemometry. 
Nanoparticles with a zeta potential above (+/-) 30 mV 
have  been  shown  to  be  stable  in  suspension,  as  the 
surface charge prohibits aggregation of the particles.
25 
These  might  result  in  stronger  repulsive  interactions  
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among the particles, and hence, higher stability of the 
particles is achieved.
26 The zeta potential can also be 
used to determine whether a charged active material is 
encapsulated  within  the  centre  of  the  nanocapsule  or 
adsorbed  onto  the  surface.
25  Zeta  potential  was 
measured by Zetasizer (Malvern instruments, England). 
The samples were diluted with 0.1 mM NaCl solution 
at a series of pH values in order to maintain a constant 
ionic strength and measured in automatic mode. Each 
sample  was  repeated  measured  three  times  and  the 
values reported were the mean value for two replicate 
samples. Zeta potential is an important consideration, 
since membranes often bear (negative) surface charge. 
Therefore, to enhance the particle cellular uptake, the 
surface  of  particles  might  be  adjusted  by  positively 
charged  surface  functional  groups.
25  Zeta  potential 
measurement  is  made  to  optimize  formulation 
parameters  and  to  make  predictions  regarding  the 
storage stability of the colloidal dispersion.
28  
 
Determination  of  drug  loading  (DL),  encapsulation 
efficiency (EE) and production yields (PY) 
DL can be done by two methods: 
• Incorporating at the time of nanoparticles production 
(incorporation method)  
• Absorbing the drug after formation of nanoparticles 
by  incubating  the  carrier  with  a  concentrated  drug 
solution  (adsorption  /absorption  technique).
29  For 
determinating  of  DL,  freeze-dried  nanoparticles  was 
dissolved in a known volume of methanol.The amount 
of VCM was quantified by measuring the absorbance at 
279.6nm .  Another  method  for determining  of  DL  is 
measuring  the  amount  of  non-entrapped  VCM  in  the 
external  aqueous  solution.  The  results  of  these  two 
methods  were  consistent.  Ideally,  a  successful 
nanoparticulate system should have a high DL capacity 
thereby  reduce  the  quantity  of  matrix  materials  for 
administration.
29 DL and EE very much depend on the 
solid-state drug solubility in matrix material or polymer 
(solid dissolution or dispersion), which is related to the 
polymer  composition,  the  molecular  weight,  the  drug 
polymer interaction and the presence of endfunctional 
groups (ester or carboxyl).
30-32 The EE of VCM in RS-
100  nanoparticles  was  determined 
spectrophotometrically (UV-160, Shimadzu, Japan)  at 
280.2 nm by measuring the amount of non-entrapped 
VCM  in  the  external  aqueous  solution  (indirect 
method)  before  freeze-drying.  The  external  aqueous 
solution  was  procured  after  centrifugation  of  the 
colloidal suspension for 20 min at 21,460×g at 25
oC. A 
standard calibration curve was plotted with the VCM 
solution (aqueous solution of 0.2% PVA). The EE (%) 
was calculated according to the following equation: 
 
 
encapsulation efficiency (%) = (actual drug content in 
nanoparticles/theoretical drug content) × 100. 
 
 
Independently of the drug-to-polymer weight ratio, the 
PY  %  (expressed  as  practical  mass  *100/Theoretical 
mass(polymer+drug) ) are relatively high.
33 All of the 
experiments were performed in triplicate. 
 
X-ray  diffraction,  Infrared  spectroscopy  and 
differential scanning calorimetry (DSC) studies 
Powder X-ray diffraction (XRD) patterns of the pure 
drug and polymer and also nanoparticles were obtained 
using  an  X-ray  diffractometer  (Siemens  D5000, 
Munich,  Germany)  equipped  with  a  graphite  crystal 
monochromator  (CuKα)  (a  voltage  of  40  KV  and  a 
current  of  20  mA)  as  X-ray  source  to  observe  the 
physical  state  of  the  drug  in  the  microspheres.  The 
scanning rate was 6°/min over the range of 5-70° and 
with an interval of 0.02°. FTIR spectra were recorded 
to assess the compatibility of the drug and polymer.
34 
The  infrared  (IR)  spectra  of  VCM  powder,  physical 
mixture  of  drug  and  polymer,  and  prepared 
nanoparticles  were  recorded  on  an  IR-
spectrophotometer(range  450-4000  cm
-1)  
(BomemHartmann & Brann, Canada) by the KBr pellet 
technique. Samples were prepared in KBr disks (2 mg 
sample in 20 mg KBr). Sample analysis were carried 
out  by  the  E2  OMNIC  software  for  analysis.  With 
reasonable intensity, the spectrum was saved for further 
analysis  at  1  cm
-1  resolution.  Differential  scanning 
calorimetry  (DSC)  was  employed  to  identify  any 
changes in the thermal behavior of VCM nanoparticles 
compared to original materials. DSC was also used to 
study the thermal behavior of the granules of the raw 
material and the film of polymers.
35 DSC analysis was 
performed  using  a  DSC-60  calorimeter  (Shimadzu, 
Japan). The instrument was equipped with a TA-60WS 
thermal analyzer,  FC-60A flow  controller and  TA-60 
software. Samples of VCM, polymer, physical mixture 
and agglomerates were located in an aluminum crucible 
and were heated ranging 25-300 °C at a scanning rate 
of 10 °C/min under a nitrogen atmosphere. A similar 
pan contain indium was used as reference. 
 
Dissolution study 
The  in  vitro  release  of  the  drug  from  the  polymeric 
nanoparticles was studied by the dialysis bag diffusion 
technique  and  under  sink  conditions  for  all 
nanoparticles  formulations.  The  dialysis  bag  retained 
nanoparticles  and  allow  the  diffusion  of  the  drug 
immediately  into  the  recipient  compartment.
36  A  set 
amount  of  nanoparticles  (20  mg  drug)  was  added  to 
200 ml dissolution medium (PBS, pH 7.4), an in vitro 
dissolution  medium  imitates  the  pH  and  salt 
concentrations in the body, preheated and maintained at 
37±1 °C in a water bath, then stirred at 100 rpm. Then 
3 ml of the medium were withdrawn at preset times by 
an automatic sampling system (Erweka DT 70, Erweka 
GmbH, Heusenstamm, Germany), (0.5, 1, 2, 3, 4, 5, 6, 
8,  12  and  24  hrs).  Each  sample  was  centrifuged  at 
21,460×g  for  10  min.  An  equal  volume  of  fresh 
medium was added after each sampling. The amount of  
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VCM in the release medium was determined by UV at 
279.8  nm.
37  Each  experiment  was  performed  in 
triplicate. 
 
Calibration curve 
Accurately weighed quantities of VCM hydrochloride 
were dissolved in a PBS, pH 7.4 to acquire solutions 
with  known  concentrations  in  the  range  of  31.25–
500g/ml.  The  spectra  of  these  solutions  were 
registered  against  the  same  medium,  and  absorption 
was measured in the 279.8 nm by spectrophotometer. 
Each experiment was performed in triplicate, After that 
the calibration graph was plotted. 
 
Perfusion solution 
The perfusion solution was prepared by dissolving 7g 
NaCl,  0.2g  KCl,  1.44  g  Na2HPO4(anhydrous)  and 
0.24g KH2PO4 in one liter of distilled water. The pH of 
prepared PBS was 7.4. preparatory experiments showed 
that  there  was  no  considerable  adsorption  of  the 
compounds on  the  tubing and  syringe.  Primary  stock 
solution  of  drug,  phenol  red  and  nanoparticles  was 
prepared in PBS.
15 Then it was diluted to 200-400μg/ml 
to  make  a  working  solution  and  standards  for 
calibration  curves  and  quality  control  samples  were 
prepared  using  serial  dilution  of  working  solution  in 
PBS.  This  range  was  selected  based  on  the 
concentration that were going to used in animal studies. 
All standards were freshly prepared for every study. 
 
In situ permeation studies 
Adult male Wistar rats (200-250 g) were housed in air 
conditioned. Rats were maintained on 12 h light- dark 
cycle and fasted 12-18 h before experiment. However 
drinking water was accessible. Rats were divided into 
control  and  test  groups.  In  each  group  three 
concentration levels of VCM (200, 300 and 400 μ g 
/ml)  were  used  in  separate  experiments.  Rats  were 
anaesthetized  using  an  intraperitoneal  injection  of 
pentobarbital (50 mg/kg) and placed on a heated pad to 
keep  normal  body  temperature.  A  small  midline  cut 
was made in the abdomen and a 10 cm section of the 
small intestine was identified and cannulated. Care was 
taken  to  handle  the  small  intestine  gently  and  to 
minimize  the  surgery  in  order  to  maintain  an  intact 
blood  reserve.  The  entire  surgical  area  was  then 
covered  with  Parafilm  to  reduce  evaporation.  Blank 
perfusion buffer was infused for 10 min by a syringe 
pump  (Palmer,  England)  followed  by  perfusion  of 
different  concentrations  (200,  300,  400  μ  g/ml)  of 
VCM (prepared from its powder or its nanoparticles) at 
a flow rate of 0.2 ml/min for 80 min. Outlet samples 
were collected at appropriate intervals (40, 50, 60, 70, 
80  min  with  half  hour  lag  time  for  balance)  in 
microtubes.  The  volume  of  sample  for  each  time 
interval  was  2  ml.  When  the  experiment  was 
completed, the length of segment was measured and the 
animal  was  euthanatized  with  a  cardiac  injection  of 
overdose of sodium pentobarbital. Samples were stored 
at -20 °C until analysis. Samples from perfusion study 
were filtered and directly injected onto HPLC column. 
Effective  permeability  coefficients  (Peff)  were 
calculated  from  the  steady-state  concentrations  of 
compounds  in  the  collected  perfusate,  which  is 
considered to be reached when the concentration level 
of  phenol  red  was  at  the  steady  state  level.  It  was 
reached  about  30  min  after  the  beginning  of  the 
perfusion, which is approved by plotting the ratio of the 
outlet  to  inlet  concentrations  (corrected  for  water 
transport)  versus  time.  The  intestinal  net  water  flux 
(NWF, μ l/h/cm) was calculated according to following 
equation: 
 
NWF= Qin(1-(Ph.redout/Ph.redin))/l 
 
Where  (Ph.red(in)) and (Ph.red(out)) are the inlet and 
outlet  concentrations  of  phenol  red.  A  negative  net 
water flux showes loss of fluid from the lumen to the 
serosal  side.  A  positive  net  water  flux  indicates 
secretion of fluid into the segment.
38 Peff was calculated 
using the following equation according to the parallel 
tube model: 
 
Peff = -Qln(Cout/Cin)/2πrℓ 
 
In which Cin is the inlet concentration and Cout is the 
outlet  concentration  of  compound  which  is  corrected 
for  volume  change  in  segment  using  phenol  red 
concentration in inlet and outlet tubing. Q is the flow 
rate (0.2 ml/min), r is the rat intestinal radius (0.18 cm) 
and  ℓ  is  the  length  of  the  segment. 
39  In  all  animal 
studies  ―Guide  to  the  care  and  use  of  experimental 
animals‖  by  Canadian  Council  on  Animal  Care,  was 
followed. 
40 The Peff for passively absorbed compounds 
is on average 3.6 times higher in humans compared to 
rats.  Solutes  with  carrier-mediated  absorption  deviate 
from this relationship, which indicates that an absolute 
scaling  of  active  processes  from  animal  to  man  is 
difficult, and therefore needs further investigation. The 
oral  fractional  absorption  of  drugs  after  oral 
administration  in  humans  (fa)  can  be  estimated  from 
this equation: 
 
Fa=1 – e
– ( 2.P eff,man .tres /r.f  ) 
 
Where tres and r are the average small intestinal transit 
time and radius in humans, and are assumed to be 3 hrs 
and 1.75cm, respectively. The relationship between our 
human  Peff  and  Fa  (from  in  vivo  pharmacokinetic 
studies),  expressed  as  correction  factor  f  was 
determined by non- linear regression. The f-value was 
then used for simulation and prediction of Fa in vivo in 
man. The f is approximately 2.8.
38 
 
Chromatographic conditions 
Perfusion  samples  were  analyzed  using  a  modified 
reversed-phase  high  performance  liquid 
chromatography  (RP-HPLC)  method.  Reverse-phase  
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HPLC  was  achieved  at  room  temperature.  HPLC 
system  containing  an  autosampler  (Hewlett-Packard 
1050  Series),  quaternary  pump  thermostat,  variable-
wavelength  UV–Vis  spectrophotometer  detector  (all 
from  Hewlett-Packard,  Waldbronn,  Germany).  The 
analytical  methodology  was  demonstrated  for 
specificity,  accuracy,  precision  and  sensitivity. 
Wavelength  ultraviolet  spectrophotometric  detector 
(Knauersmartline 2500) set at 430 nm and 254 nm for 
phenol  red  and  VCM,  respectively.  EZChrom  Elite 
version  2.1.7  was  used  for  data  attainment,  data 
reporting  and  analysis.  The  mobile  phase  for  VCM 
analysis  consisted  of  30%  (v/v)  methanol  and  70% 
(v/v)  of  glacial  acetic  acid  aqueous  solution  (0.75%) 
adjusted to pH 5.5. For phenol red analysis the mobile 
phase  consisted  of  45%  (v/v)  KH2PO4  0.05  M  and 
55% (v/v) methanol adjusted with triethanol amine to 
pH 2.6. The mobile phases were filtered with a 0.45 
mm pore size cellulose membrane filter, and degassed 
before  use.  Analytical  column  used  for 
chromatographic  separations  was  packed  with 
Adsorbosil  ODS  C18  (250  ×  4.6  mm)  5  µm  with 
precolumn. 20  μl of  samples or  calibration  standards 
were injected directly onto the column and were eluted 
with  a  gradient  consisting  of  phosphate  buffer.  Until 
termination of the run at 20 min, the flow rate was 1 
ml/min. The system was equilibrated for 20 min under 
the starting conditions before injecting the next sample. 
Under the mentioned conditions the retention times for 
VCM  and  phenol  red  were  5  min  and  13.8  min, 
respectively.  Runs contained quality control samples 
(QC) at three concentrations levels. Calibration curves 
were  acquired  by  plotting  the  phenol  red  and  VCM 
peak  area  against  their  concentrations  in  standard 
solutions.
41,42  Each  determination  was  carried  out  in 
triplicate (SD within 0.09). 
 
Results  
Micromeritics properties 
Encapsulation  efficiencies  of  VCM  nanoparticles  are 
reported in Table 1. It is evident from Table 1 that the 
encapsulation  efficiency  was  affected  by  the  ratio  of 
drug:polymer. Mean particle diameter and production 
yield of the different nanoparticles are also shown in 
Table  1.  The  encapsulation  efficiency  of  the  drug 
depended on the solubility of the drug in the solvent 
and  continuous  phase.  Youan  &  et  al.  have  been 
reported  Similar  observation.  VCM  is  insoluble  in 
organic solvents used to dissolve the polymer and thus 
cannot  migrate  from  the  internal  into  the  external 
aqueous  phase  via  diffusion  through  the  organic 
polymer  solution.  Entrapment  efficiency  of 
polypeptides was increased by enhancing the viscosity 
creators.
43  Despite  the  hydrosolubility  of  VCM, 
favoring  the  leakage  of  the  drug  into  the  external 
aqueous  phase,  entrapment  efficiencies  were  rather 
high.  It  is  assumed  that  VCM  is  localized  at  the 
interfaces (either internal water in oil or external oil in 
water).  Therefore  a  considerable  amount  of  drug  is 
supposed  to  be  adsorbed  at  the  outer  surface.  In 
addition, the elimination of the organic solvent under 
reduced  pressure  favors  its  fast  evaporation  followed 
by  the  polymer  precipitation,  thus  reducing  the 
movement  of  the  drug  to  the  external  phase.  At  the 
ratio  of  drug  to  polymer  1:3  the  amount  of  drug 
entrapment  was  23.69%  which  was  very  near  to  the 
theoretical value (25%). 
The particle size data show that prepared nanoparticles 
were  of  submicron  size  and  of  small  polydispersity, 
which  indicated  a  relatively  narrow  particle  size 
distribution. An increase in particle size from 362 nm 
to  499  nm  with  a  decrease  in  the  theoretical  drug 
loading was also observed (Table 1). As it can be seen, 
the particles size are increased with increasing polymer 
amount.
44,45  When  the  dispersed  phase  with  higher 
viscosity  was  poured  into  the  dispersion  medium, 
bigger droplets were formed with larger mean particle 
size.  It  has  also  been  reported  that  the  particle  size 
increases  with  increasing  the  content  in  hydrophobic 
polymer. It can be assigned to that fact that with the 
higher diffusion rate of non-solvent to polymer solution 
the smaller size of nanocapsules is easily obtained.
46 A 
volume-based  size  distribution  of  drug,  polymer,  and 
drug-loaded  nanoparticles  indicated  a  log–probability 
distribution.  The  increase  in  drug  content  of  the 
nanoparticles  with  increased  theoretical  drug  loading 
has emerged in the decreased particle sizes displayed 
(p<0.05).  
 
Table 1.Effect of drug: polymer ratio on drug loading efficiency, production yield, particle size zeta potential and polydispersity index of 
vancomycin nanoparticles 
Formulation 
code 
Drug: 
polymer 
ratios 
Production 
yield 
(%±SD) 
Theoretical 
drug 
Content 
(%) 
Mean drug 
Entrapped 
(%±SD) 
Drug 
loading 
efficiency 
(%±SD) 
Mean 
particle 
Size 
(nm±SD) 
Zeta 
Potential 
(mV±SD) 
Polydispersity 
Index 
(PDI) 
F1  1:1  96.38 ±1.65  50  30.25 ±1.04  63 ± 2.19  362±29.26  18.1±8.82  0.0099 
F2  1:2  97.84 ±1.54  33.33  29.79 ±1.12  89.37±2.36  430±31.94  25.7±9.72  0.0055 
F3  1:3  98.35 ±1.87  25  23.69 ±1.02  94.76± 1.95  499 ± 110  24.1±7.17  0.0034 
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The average yield of 97% is in the normal range does 
not indicate any unexpected vanishment of products. 
Zeta potential is the potential difference the dispersion 
medium  and  stationary  layer  of  fluid  attached  to  the 
dispersed particles. The significance of zeta potential is 
that  its  value  can  be  pertained  to  the  stability  of 
colloidal dispersion.
28 The zeta potential indicates the 
degree  of  repulsion  between  near,  similarly  charged 
particles  in  dispersion.  As  to  the  zeta  potential,  the 
larger  its  absolute  value  is,  the  more  likely  the 
suspension is to be stable, since the charged particles 
repel one another and thus defeat their natural tendency 
to  aggregate.
47  The  zeta  potential  measurements 
showed  posetively-charged  particle  surfaces,  varying 
from  18.1  to  25.7mV.  Drug-loaded  nanoparticle 
indicated  positive  charge,  because  VCM  is  cationic 
drug and changed the charge of nanoparticles. All the 
gained values were then acceptable and favoring a good 
stability.  The  zeta  potential  of  three  nanosphere 
formulations is shown in Table 1. Blank nanoparticles 
like nanoparticles had a positive charge (15.7 mV).  
 
DSC Analysis 
DSC  was  employed  to  study  the  crystallinity  of 
nanoparticles. DSC studies were carried out to confirm 
compatibility.
48  The  thermal  behavior  of  drugs, 
physical  mixture  of  drug  and  polymer,  and 
formulations  was  studied.  Any  sudden  or  forceful 
change in the thermal behavior of the drug or polymer 
may indicate a possible drug-polymer interaction.
49 The 
endothermic  peak  of  the  pure  drug  was  observed  at 
about 82.10°C (Figure 1) and Eudragit RS100 showed 
an amorphous state. The physical mixture of VCM and 
RS100 showed nearly the same thermal behavior as the 
individual  components,  indicating  that  there  was  no 
interaction  between  the  drug  and  the  polymer  in  the 
solid  state.  Indeed,  in  the  thermogram  of  the 
nanoparticles  containing  Eudragit  RS,  there  was 
endothermic  peak  at  219.92°C  which  accords  to  the 
melting point of drug in the nanoparticles. In the DSC 
curve  of  physical  mixture  of  drug  and  polymer,  and 
formulations F1, F2 and F3, the characteristic peaks of 
drug were observed. The results showed that there is no 
incompatibility between drug and polymers. 
 
Powder X-ray diffractometry 
XRPD  is  a  powerful  tool  to  identify  any  changes  in 
crystallinity of drug (polymorphism).
50 Comparison of 
the  X-ray  diffraction  patterns  of  VCM  and 
nanoparticles prepared with RS-100 (Figure 2) showed 
no  remarkable  reduction  in  the  peak  intensities, 
suggesting that the expanse of VCM crystallinity was 
not  reduced  by  the  polymer.  The  X-ray  diffraction 
patterns of pure drug and Eudragit RS showed that the 
pure drug is crystalline in nature (Figure 2). As shown 
in  Figure  2,  Eudragit  RS100  is  a  typical  form  of 
amorphous  materials,  whereas  the  pure  drug  showed 
the  diffractographic  profile  of  a  crystalline  material. 
When  the  nanoparticles  were  prepared  with  different 
polymer/drug ratios (F1, F2 and F3) it is clear that the 
nanoparticles  with  lower  polymer  concentration 
showed  similar  peaks  as  the  blank  nanoparticles.  At 
high concentration of polymer and low concentration of 
drug  some  of  the  distinguishing  peaks  for  VCM  are 
detectable  but  with  very  low  intensity  due  to  the 
presence of lower concentration of drug in the sample 
in comparison with pure VCM sample. This confirms 
the results obtained from DSC. 
 
 
Figure 1. DSC thermogram of the VCM; RS100; PVA; physical mixture F2; blank 
nanoparticles, VCM nanoparticles formulations as F1, F2 and F3. 
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Figure 2. X-ray diffraction a) VCM; b) RS100; c) Physical Mixture F2; d) blank nanoparticles;  
e) VCM : RS100 (1:1); f) VCM : RS100 (1:2); g) VCM RS100 (1:3). 
 
FTIR Studies 
The  FTIR  spectra  of  VCM,  VCM-loaded  RS-100 
nanoparticles,  physical  mixture  F2  (1:1),  and  the 
individual components are portrayed in Figure 3. The 
FTIR of VCM showed phenolic OH at 3257.39 cm
-1, 
aromatic  C=C  stretching  at  1652.7  cm
−1  and  C=O 
stretching  at  1503.48  cm
-1.  The  peaks  in  the  range 
between    2800  and    3100cm
-1  pertain  to  the  C—H 
stretching bands, the peak in the range between 1650 
and 1800cm
-1 is due to the C=O stretching vibrational 
groups, and the peak in the range between 1350 and 
900 cm
-1 corresponds to the C—O stretching vibration 
mode.  The peaks within 2950–3000 cm
-1 assigned to 
the stretching vibrations of CH2 and CH3, the peak at 
1763 cm
-1 conforms the C=O ester vibration, and the 
peak  at  1153  cm
-1  is  fitted  with  the  C—O  ester 
vibration,  respectively.  Eudragit  RS-100  has  C=O 
stretching band at 1734.2  cm
-1. Nanoparticles F1,  F2 
and F3 have C=O stretching band at 1731.2, 1733.7, 
1733.96 cm
-1, respectively (Figure 3). After VCM was 
encapsulated  into  the  nanoparticles,  the  characteristic 
peaks for VCM showed by the stronger intensity peaks 
for  of  matrix  materials.  On  the  other  hand,  the  C=O  
stretching  bands  of  VCM  in  polymeric  systems  were 
merged,  thus  leading  to  a  peak  shifting  from  1731.2 
cm
-1  to  1733.96  cm
-1.
51  The  bands  observed  for 
nanoparticles  spectrum  showed  similar  unique  peaks 
but with smaller intensity due to low concentration of 
drug in nanoparticles. No differences in the positions of 
the absorption bands were observed in spectra of the 
VCM  physical  mixture  with  RS-100,  indicating  that 
there  are  no  chemical  interactions  in  the  solid  state 
between the drug and the polymer. This suggests that 
there was no new chemical bond constructed between 
these  functional  groups  in  the  drug  and  the  polymer 
after  preparing  the  nanoparticles  and  the  results 
confirmed that the drug is physically dispersed in the 
polymer.  FTIR  investigations  confirmed  the 
compatibility of VCM and RS100. 
 
In vitro release study 
The mean cumulative release (%) versus time curves is 
shown in Figure 4. The rate of dissolution of physical 
mixture  is  quite  fast,  and  more  than  96%  drug  is 
dissolved in about 30 min and 100% by 60 min. The 
drug release from the nanoparticles manifested to have 
two  components  with  an  immediate  release  of  about 
10.78-12.27% at the first sampling time of 30 min. This 
was  followed  by  a  slower  exponential  release  of  the 
remaining drug over the next 6-8 h. The in vitro VCM 
release profiles from drug-loaded nanoparticles are also 
illustrated  in  Figure  4.  Furthermore,  Figure  4  clearly 
presentes  that  the  rate  of  drug  release  from  the 
nanoparticles  depended  on  the  polymer  concentration 
in  the  system.  A  similar  relationship  was  observed 
between  polymer  content  and  drug  release  rate  from 
prepared  nanoparticles.  By  decreasing  the 
concentration of the polymer in the system, an increase 
was shown in the release rate of VCM. The difference 
was also not significant (p > 0.05) for 0.5 or 24 h. It is 
offered  that  a  reduced  diffusion  path  and  increased 
tortuosity may have retarded the drug release rate from 
the matrix at the presence of polymer matrix.  
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Figure 3. FTIR spectrum; a) RS100; b) VCM; c) Physical Mixture F2; d) blank nanoparticles;  
e) VCM : RS100 (1:1), f) VCM : RS100 (1:2), g) VCM : RS100 (1:3). 
 
 
Figure4. Cumulative percent release of VCM nanoparticles prepared with different drug-to-polymer ratio and physical mixture F2. 
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Nanoparticles  containing  1:1  (F1)  released  the  drug 
more rapidly, wherease F3 exhibited a relatively slower 
drug release profile. F1, F2 and F3 nanoparticles showed 
higher dissolution efficiency of 81.44, 76. 25 and 66. 
37%,  respectively.  Physical  mixture  of  drug  and 
polymer  exhibited  higher  release  in  comparison  with 
microspheres  (p<  0.05)  (Table  2  &  Figure  4).  The 
presence  of  Eudragit  RS100  in  the  matrix  of 
nanoparticles  caused  a  slower  and  more  advancing 
release of VCM during the time of the experiment.
52  
The lowest  dissolution efficiency  was  showed  for  F3 
(66.  37%)  and  dissolution  efficiency  of  the  physical 
mixture was 98.03% (p< 0.05). The value of t50% varies 
between  2.24  (F2  formulation)  to  4.85  h  (F3 
formulation).  The  results  of  difference  factor  (f2) 
observed that there is no similarity between the release 
profiles  of  nanoparticle  formulations  and  physical 
mixture (Table  2).  The  in  vitro  release  profiles  were 
fitted  to  various  kinetic  models  (Higuchi,  first-order, 
zero-order,  Peppas,  Hixson  crowell,  square  root  of 
mass,  three  second  root  of  mass,  weibull,  linear 
probability and log- probability) in order to determine 
the mechanism of drug release.
23 The dissolution rate 
constants  were  calculated  from  the  slope  of  the 
respective plots and high correlation was observed for 
the Peppas models (Table 3). The data obtained were 
also put in Korsemeyer-Peppas model in order to find 
out  n  value,  which  particularizes  the  drug  release 
mechanism.  The  n  value  of  nanospheres  of  different 
drug  to  polymer  ratio  was  between  0.392-0.569, 
indicating that the mechanism of the drug release were 
diffusion controlled.  
 
Table 2.Comparison of various release characteristics of vancomycin from different nanoparticle formulations and physical mixture 
Formulation 
at 50%
 (h) 
bDE 
cQ0.5 
dQ24 
Difference Factor 
(f1) 
F1  3.25  81.44  11.44±0.99  95.03±2.17  38.11 
F2  2.24  76.25  12.27±1.25  88.27±0.77  40.52 
F3  4.85  66.37  9.95±0.49  82.23±0.78  52.55 
Physical mixture  0.26  98.03  96.10±0.43  98.70±0.52  0.04 
adissolution time for 50% fractions. 
bDissolution Efficiency. 
camount of drug release after 0.5h.
d amount of drug release after 24h 
Intestinal permeability and oral fractional absorption 
data 
In  any  in  situ  intestinal  perfusion  technique  it  is 
necessary  to  determine  the  magnitude  of  volume 
changes  of  the  solution  in  the  gut  lumen  during  an 
experiment.  For  this  purpose  phenol  red  dye  (200  µ 
g/ml) was added to drug solution in each experiment. 
Phenol  red  was  used  as  a  non-absorbable  marker  to 
detect  gain  or  loss  of  water  by  the  lumen.  The 
determined  mean  Peff  values  for  different 
concentrations of vancomycin and its nanoparticles in 
PBS, oral fractional absorption and also the mean net 
water fluxes in the SPIP technique are listed in Table 4. 
 
Discussion 
The organic phase (O) behaves as a barrier between the 
two aqueous compartments. To control the methylene 
chloride  elimination  time  and  rate,  we  used  a  rotary 
evaporator method. Thus, the transfer of the drug into 
the  external  phase  (W2)  was  hampered.  The  particle 
formation itself is based on coacervation. The solvent is 
extracted  from  the  polymer  containing  organic  phase 
because of its initial diffusion into the continuous W2 
phase, motivating phase separation of the polymer. The 
organic solvent  is eliminated  by  two steps;  firstly  by 
extraction and secondly by evaporation. In general, the 
solvent removal rate directly affects the encapsulation 
efficiency of  a  drug
53,  54 because  the  slow  membrane 
formation rate may reduce the encapsulation efficiency 
as a result of improving the chances of drug molecules 
to be diffused out from the inner W1 phase to outer W2 
water  phase.
54,55  It  is  deduced  that  rapid  membrane 
formation  is  an  important  criterion  preventing  the 
leakage of VCM to the W2 phase. Generally, PVA is 
used as a surfactant in the W1/O/W2 emulsion method 
to  comprise  it  onto  the  surface  of  RS-100  particles, 
thereby lowering the surface tension between the RS-
100  surface and the W2 phase.
54,56 However, because 
PVA cannot be washed away absolutely, it remains on 
the  surface  of  RS-100.
54,57  PVA  concentration  in  the 
external water phase is known to be a important factor 
to influence the size of nanoparticles.
43 The low drug 
incorporation efficiency may be ascribed to the water 
soluble nature of VCM hydrochloride. This led to its 
rapid  partitioning  into  the  aqueous  phase  and 
accordingly  decreased  entrapment  into  the 
nanoparticles  during  polymer  deposition.  The 
decreased drug entrapment with increasing theoretical 
drug  loadings  is  due  to  an  enhanced  drug  exudation 
into the aqueous phase at high loadings. 
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Table 3.Fitting parameters of the in vitro release data to various release kinetic models for nanoparticles 
 
F1 
ORDER  RSQ  Slope  intercept  MPE%  K 
Zero order  0.627  0.036  0.341  3.1E+14  0.036 
First  order  0.891  -0.152  -0.314  2.5E+14  -0.152 
Second  order  0.950  1.320  -2.217  1.7E+15  1.320 
Higuchi  0.876  0.220  0.103  9.3E+13  0.220 
Peppas (Power Low)  0.999  0.569  -1.404  15.8656  1.767 
Hixson-Crowell  0.816  0.029  0.122  2.9E+14  0.029 
Square root of mass  0.770  0.034  0.184  3E+14  0.034 
Three-seconds root of mass  0.722  0.036  0.242  30.1957  0.036 
weibull  0.998  0.583  -0.857  15.6951  0.230 
Linear-probability  0.323  0.197  -1.446  5.5E+13  0.197 
Logarithmic-probability  0.911  0.160  0.198  59.8762  0.160 
 
F2 
Zero order  0.543  0.034  0.335  3046748  0.034 
First  order  0.714  -0.094  -0.459  3344353  -0.094 
Second  order  0.855  0.353  0.497  3018450  0.353 
Higuchi  0.819  0.212  0.098  889793  0.212 
Peppas (Power Low)  0.995  0.393  -1.218  32.3218  1.481 
Hixson-Crowell  0.656  0.022  0.138  3271499  0.022 
Square root of mass  0.627  0.027  0.197  3222189  0.027 
Three-seconds root of mass  0.598  0.031  0.248  3167227  0.031 
weibull  0.986  0.410  -0.744  33.1694  0.163 
Linear-probability  0.339  0.142  -1.043  1349436  0.142 
Logarithmic-probability  0.868  0.155  0.066  61.8763  0.155 
 
F3 
Zero order  0.686  0.034  0.226  2054809  0.034 
First  order  0.834  -0.077  -0.238  1926127  -0.077 
Second  order  0.925  0.213  0.102  841078  0.213 
Higuchi  0.905  0.199  0.016  149265  0.199 
Peppas (Power Low)  0.994  0.414  -1.515  30.4708  1.512 
Hixson-Crowell  0.788  0.019  0.080  2014231  0.019 
Square root of mass  0.763  0.025  0.119  2037665  0.025 
Three-seconds root of mass  0.738  0.029  0.157  2050986  0.029 
weibull  0.986  0.427  -1.179  34.4088  0.063 
Linear-probability  0.377  0.139  -1.359  791204  0.139 
Logarithmic-probability  0.871  0.155  -0.301  66.9204  0.155 
Physical 
mixture 
Zero order  0.081  0.012  0.828  7526441  0.012 
First  order  0.016  0.072  -6.560  9078026  0.072 
Second  order  0.042  -8796.400  153390.990  9090842  -8796.367 
Higuchi  0.261  0.112  0.669  6082596  0.112 
Peppas (Power Low)  0.982  0.508  -0.724  25.1718  1.662 
Hixson-Crowell  0.032  0.007  0.722  8895392  0.007 
Square root of mass  0.060  0.010  0.781  8656034  0.010 
Three-seconds root of mass  0.074  0.011  0.808  8326018  0.011 
weibull  0.973  0.574  0.991  4.88962  5.616 
Linear-probability  0.022  0.053  1.901  8830365  0.053 
Logarithmic-probability  0.837  0.281  2.517  10.1867  0.281 
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Table 4. Permeability coefficients and oral fractional absorption determined in rats for test and control groups 
Group  Cin 
Mean Puff 
(×10
5 cm/sec) 
Oral fractional 
absorption 
Mean NWF 
(ml/min/cm) 
Control 
200  6.11(± 2.66)  0.37(± 0.17)  0.0003(± 0.0002) -  
300  3.87(± 2.45)  0.53(± 0.09)  0.0006(± 0.0003)  
400  2.54 (± 1.64)  0.28(± .012)  0.0004(± 0.0001)  
Test 
200  17.88 (± 2.61)  0.45(± 0.15)    0.0005(± 0.0002) -  
300  16.63(± 2.98)  0.77(± 0.13)  0.0004(± 0.0002)  
400  15.75(± 4.47)  0.42(± 0.20)  -0.0006(± 0.0003)  
 
 
Zeta  potential  results  (Table  1)  showed  that  drug-
loaded  formulations  carried  a  positive  charge,  which 
assists  particle  stability  because  the  repulsive  forces 
prevent  aggregation  with  aging.  It  has  been  reported 
that the positive charge of RS-100 nanoparticles is due 
to positive charge of VCM,.
58 because VCM is cationic 
drug and  changed  the  charge  of  nanoparticles.  Drug-
free  RS-100    nanoparticles  had  a  positive  surface 
charge  of  15.  7  mV,  which  can  be  attributed  to  the 
presence of carboxyl groups and quaternary ammonium 
of  the  polymer  on  the  nanoparticles.
30  Zeta  potential 
measurements  showed  a  insignificant  increase  in 
positivity (from 18.1 mV to 25.7 mV) with an decrease 
in  theoretical  drug  loadings.  These  findings  are 
concuring  to  what  was  expected,  for  instance  a 
decrease in the surface positivity due to interaction of 
carboxyl groups and the cationic drug on the particle 
surface.  The  increase  in  nanoparticle  size  with 
decreases  in  the  theoretical  drug  loading  of  VCM 
(Table  1)  may  possibly  have  influenced  the  surface 
charge of the RS-100  nanoparticles.
59 From the data it 
is obvious that all the formulations are almost unstable 
in the colloidal state. This indicates that the particles 
should not be stored in a liquid suspension form and 
rather they should be stored in a lyophilized state.
59The 
rapid initial release of VCM was probably due to the 
drug which was adsorbed or near to the surface of the 
nanoparticles and the large surface to volume ratio of 
nanoparticle geometry because of their size. 
30 It may 
also be due to the water soluble nature of VCM. The 
exponential  delayed  release  may  be  attributed  to 
diffusion of the dissolved drug within the RS-100 core 
of  the  nanoparticle  into  the  dissolution  medium. 
Similar observations were reported by other researchers 
working.
  60,61 Loading  of  VCM  into  the  nanoparticles 
prompts  to  a  modification  of  in  vitro  drug  release, 
depending  on  their  combination  .  The  data  obtained 
were also put in Korsemeyer-Peppas model in order to 
perceive the n value, which describes the drug release 
mechanism.  The  n  value  of  nanospheres  of  different 
drug:polymer ratio was  between 0.39-0.56,  indicating 
that the drug release was diffusion controlled (Table 3). 
On the other hand, from the acquired results in rats it is 
demonstrated  that  the  intestinal  permeability  oral 
fractional absorption of VCM is significantly increased 
using its nanoparticles in all three concentrations which 
were  used  (P  <  0.05).  The  stable  water  fluxes  and 
permeability  coefficients  in  each  perfusion,  as  a 
function of time, for tested compounds indicated that 
intestinal  barrier  function  was  maintained  during  the 
methodology. The intestinal permeability of VCM was 
determined  to  be  in  the  range  of  1.96  (±1.09)×10
-
5cm/sec to 4.66 (±1.32)×10
-5 cm/sec in control groups. 
regardless,  the  drug  permeability  in  test  groups' 
intestinal  segments  which  were  perfused  by  VCM 
nanoparticles in PBS, ranged between 3.68 (±2.82)×10
-
5  cm/sec  and  10.06  (±2.61)×10
-5  cm/sec.  There  were 
statistical differences among the Peff values in different 
concentrations. The maximum permeability, was  seen 
at  doses  of  300  µg/ml.  Therefore,  it  seems  that  the 
intestinal  permeability  of  VCM  is  not  concentration-
dependent. The oral fractional absorption of VCM was 
determined to be in the range of 0.28 (±0.12) to 0.53 
(±0.09)  in  control  groups,  while  the  test  group  was 
determined to be in the range of 0.42 (±0.20) to 0.77 
(±0.13) (Table 4).  In view of the hydrophilicity and 
high molecular weight of the peptidic drug, VCM, the 
higher  intestinal  permeability  after  nanonization  is 
probable  due  to  enhanced  paracellular  passage  and 
endocytotic  uptake,  because  the  particles  with    small 
size  are  absorbed  by  intestinal  enterocytes  through 
endocytosis. Coating of VCM nanoparticles with PVA, 
a bioadhesive material, can also be a tactic to increase 
nanoparticle  uptake  by  intestinal  enterocytes. 
Nanoparticles coated with bioadhesive materials were 
contemplated to develop mucoadhesion. Adhesion of a 
carrier  system  to  the  mucus  may  improve  residence 
time and drug contact with the underlying epithelium, 
thus increasing drug intestinal permeability which was 
demonstrated in the present study. 
 
Conclusion 
VCM-loaded  RS-100  nanoparticles  were  successfully 
provided  by  using  W1/O/W2  double-emulsion  solvent 
evaporation  method.  Drug  release  from  nanoparticles 
was more sustained than physical mixture. Moreover,  
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the intestinal permeation  and fractional absorption of 
VCM were improved using its nanoparticles and  this 
may  allow  more  efficient  therapy  compared  to  VCM 
formulations present in the market. 
 
Acknowledgments 
The  financial  support  from  biotechnology  center, 
Tabriz  University  of  Medical  Sciences,  is  greatly 
acknowledged. 
 
Conflict of interest 
The authors report no conflicts of interest in this work. 
 
References 
1.  Robles-Piedras AL, Gonz،lez-Lpez EH. Therapeutic 
Drug  Monitoring  of  Vancomycin.  Proc  West 
Pharmacol Soc 2009;52:21-3. 
2.  Moellering RC Jr. Monitoring Serum Vancomycin 
Levels: Climbing the Mountain Because It Is There? 
Clinical infectious diseases 1994;18:544-6. 
3.  Cook  FV,  Farrar  WE.  Vancomycin  revisited. 
Annals of internal medicine 1978; 88(6): 813-8. 
4.  Bryan CS, White WL. Safety of oral vancomycin in 
functionally anephric patients. Antimicrobial Agents 
and Chemotherapy 1978; 14(4): 634-35. 
5.  Geraci  JE,  et  al.  Some  laboratory  and  clinical 
experiences  with  a  new  antibiotic,  vancomycin.  
Antibiot Annu 1956-1957:90-106. 
6.  Florence AT. Nanoparticle uptake by the oral route: 
Fulfilling  its  potential?  Drug  discovery  today: 
technologies 2005; 2(1):75-81. 
7.  Yallapu  MM,  et  al.  Fabrication  of  curcumin 
encapsulated  PLGA  nanoparticles  for  improved 
therapeutic  effects  in  metastatic  cancer  cells. 
Journal  of  colloid  and  interface  science  2010; 
351(1): 19-29. 
8.  Kumar GS, et al. Synthesis and characterization of 
bioactive hydroxyapatite-calcite nanocomposite for 
biomedical  applications.  Journal  of  colloid  and 
interface science 2010; 349(1): 56-62. 
9.  Nouvel C, et al. Biodegradable nanoparticles made 
from  polylactide-grafted  dextran  copolymers . 
Journal  of  colloid  and  interface  science  2009; 
330(2): 337-43. 
10. Han  DP,  et  al.  Spectrum  and  susceptibilities  of 
microbiologic  isolates  in  the  Endophthalmitis 
Vitrectomy  Study.  American  journal  of 
ophthalmology 1996; 122(1): 1-17. 
11. Jelvehgari  M,  et  al.  Formulation,  characterization 
and  in  vitro  evaluation  of  theophylline-loaded 
Eudragit  RS  100  microspheres  prepared  by  an 
emulsion-solvent  diffusion/evaporation  technique. 
Pharmaceutical  Development  and  Technology 
2011;16:637-44. 
12. Valizadeh  H,  et  al.  A  simple  and  rapid  high-
performance  liquid  chromatography  method  for 
determining  furosemide,  hydrochlorothiazide,  and 
phenol  red:  applicability  to  intestinal  permeability 
studies. J AOAC Int 2006; 89(1): 88-93. 
13. Zakeri-Milani,P,  et  al.  Biopharmaceutical 
classification  of  drugs  using  intrinsic  dissolution 
rate  (IDR)  and  rat  intestinal  permeability.  Eur  J 
Pharm Biopharm 2009; 73(1): 102-6. 
14. Zakeri-Milani P, et al. Investigation of the intestinal 
permeability  of  ciclosporin  using  the  in  situ 
technique  in  rats  and  the  relevance  of  P-
glycoprotein.  Arzneimittelforschung  2008;  58(4): 
188-92. 
15. Zakeri-Milani P, et al. Predicting human intestinal 
permeability  using  single-pass  intestinal  perfusion 
in rat. J Pharm Pharm Sci 2007; 10(3): 368-79. 
16. Zakeri-Milani  P,  et  al.  The  utility  of  rat  jejunal 
permeability  for  biopharmaceutics  classification 
system. Drug Dev Ind Pharm 2009; 35(12): 1496-
502. 
17. Dashevsky A, Zessin G. The effect of ethylcellulose 
molecular weight on the properties of theophylline 
microspheres. Journal of microencapsulation 1997; 
14(3): 273-80. 
18. Saravanan  M,  et  al.  Ibuprofen-loaded 
ethylcellulose/polystyrene  microspheres:  an 
approach to get prolonged drug release with reduced 
burst effect and low ethylcellulose content. Journal 
of microencapsulation 2003; 20(3): 289-302. 
19. Benichou  A,  Aserin  A,  Garti  N.  Polyols,  high 
pressure,  and  refractive  indices  equalization  for 
improved  stability  of  W/O  emulsions  for  food 
applications.  Journal  of  dispersion  science  and 
technology 2001; 22(2-3): 269-80. 
20. Fagerholm  U,  Johansson  M,  Lennernas  H. 
Comparison between permeability coefficients in rat 
and  human  jejunum.  Pharmaceutical  research 
1996; 13(9): 1336-42. 
21. Shantha  Kumar  TR,  et  al.  Validated  HPLC 
analytical  method  with  programmed  wavelength 
UV  detection  for  simultaneous  determination  of 
DRF-4367 and  Phenol red  in rat  in situ  intestinal 
perfusion  study.  Journal  of  pharmaceutical  and 
biomedical analysis 2005; 38(1): 173-9. 
22. Favetta P, et al. New sensitive assay of vancomycin 
in  human  plasma  using  high-performance  liquid 
chromatography  and  electrochemical  detection. 
Journal of Chromatography B: Biomedical Sciences 
and Applications 2001; 751(2): 377-382. 
23. Hoffart  V,  et  al.  Low  molecular  weight  heparin-
loaded  polymeric  nanoparticles:  formulation, 
characterization,  and  release  characteristics.  Drug 
Dev Ind Pharm 2002; 28(9): 1091-9. 
24. Hasan AS, et al,.. Effect of the microencapsulation 
of nanoparticles on the reduction of burst release. 
Int J Pharm 2007; 344(1-2): 53-61. 
25. Couvreur  P,  et  al.  Nanocapsule  technology:  a 
review. Critical reviews in therapeutic drug carrier 
systems 2002; 19(2): 99-134. 
26. Agnihotri  SM,  Vavia  PR.  Diclofenac-loaded 
biopolymeric  nanosuspensions  for  ophthalmic 
application. Nanomedicine 2009; 5(1): 90-5.  
|   55 
Vancomycin -Eudragit RS Nanoparticles Statistical Optimization of Oral Vancomycin-Eudragit RS 
Advanced Pharmaceutical Bulletin, 2012, 2(1), 43-56  Copyright © 2012 by Tabriz University of Medical Sciences 
27. Foster  KA,  Yazdanian  M,  Audus  KL. 
Microparticulate uptake mechanisms of invitro cell 
culture  models  of  the  respiratory  epithelium. 
Journal  of  pharmacy  and  pharmacology  2001, 
53(1): 57-66. 
28. Mehnert  W,  Mäder  K.  Solid  lipid  nanoparticles: 
Production,  characterization  and  applications. 
Advanced  Drug  Delivery  Reviews  2001;  47(2-3): 
165-96. 
29. Mohanraj  V,  Chen  Y.  Nanoparticles-a  review. 
Tropical Journal of Pharmaceutical Research 2007; 
5(1): 561-73. 
30. Govender T, et al. PLGA nanoparticles prepared by 
nanoprecipitation: drug loading and release studies 
of  a  water  soluble  drug.  Journal  of  Controlled 
Release 1999; 57(2): 171-85. 
31. Govender T, et al. Defining the drug incorporation 
properties of PLA-PEG nanoparticles. International 
journal of pharmaceutics 2000; 199(1): 95-110. 
32. Panyam  J,  et  al .Solidstate  solubility  influences 
encapsulation  and  release  of  hydrophobic  drugs 
from  PLGA/PLA  nanoparticles.  Journal  of 
pharmaceutical sciences 2004; 93(7): 1804-14. 
33. Gavini E, et al. PLGA microspheres for the ocular 
delivery  of  a  peptide drug,  vancomycin  using 
emulsification/spray-drying  as  the  preparation 
method: in vitro/in vivo studies. European journal 
of  pharmaceutics  and  biopharmaceutics  2004; 
57(2): 207-12. 
34. Mukherjee  B,  et  al.  A  comparison  between 
povidone-ethylcellulose  and  povidone-eudragit 
transdermal dexamethasone matrix patches based on 
in  vitro  skin  permeation.  European  journal  of 
pharmaceutics and biopharmaceutics 2005; 59(3): 
475-83. 
35. Lin  SY  Yu  HL.  Microscopic  fourier  transform 
infrared/differential  scanning  calorimetry  system 
used  to  study  the  different  thermal  behaviors  of 
polymethacrylate copolymers of Eudragits RS, RL, 
E 30D,  or E.  Journal of  applied polymer  science 
2000; 78(4): 829-35. 
36. Gribb  AA  ,Banfield  JF.  Particle  size  effects  on 
transformation  kinetics  and  phase  stability  in 
nanocrystalline TiO2. American Mineralogist 1997; 
82(7): 717-28. 
37. Kumar GS, et al. Synthesis and characterization of 
bioactive hydroxyapatite-calcite nanocomposite for 
biomedical  applications.  J  Colloid  Interface  Sci 
2010; 349(1): 56-62. 
38. Fagerholm  U,  Johansson  M,  Lennernas  H. 
Comparison between permeability coefficients in rat 
and  human  jejunum.  Pharm  Res  1996;  13:  1336-
1342. 
39. Amidon  GL,  et  al.  A  theoretical basis  for  a 
biopharmaceutic drug classification: the correlation 
of  in  vitro  drug  product  dissolution  and  in  vivo 
bioavailability.  Pharmaceutical  research  1995; 
12(3): 413-20. 
40. Olfert  ED,  et  al.  Guide  to  the  care  and  use  of 
experimental  animals.  Vol.  1.  1993:  Canadian 
Council on Animal Care Ottawa, Ontario, Canada. 
41. Danzer L. Liquid-chromatographic determination of 
cephalosporins  and  chloramphenicol  in  serum. 
Clinical chemistry 1983; 29(5): 856-8. 
42. Swenson  ES,  Milisen  WB,  Curatolo  W.  Intestinal 
permeability  enhancement:  efficacy,  acute  local 
toxicity, and reversibility. Pharmaceutical research 
1994; 11(8): 1132-42. 
43. Youan  BBC,  et  al.  Protein  release  profiles  and 
morphology  of  biodegradable  microcapsules 
containing  an  oily  core.  Journal  of  controlled 
release 2001; 76(3): 313-26. 
44. Pignatello  R,  et  al.  Properties  of  tolmetin-loaded 
Eudragit  RL100  and  Eudragit  RS  100 
microparticles  prepared  by  different  techniques. 
STP pharma sciences 1997;7(2): 148-57. 
45. Malamataris  S,  Avgerinos  A.  Controlled  release 
indomethacin  microspheres  prepared  by  using  an 
emulsion solvent-diffusion technique. International 
Journal of Pharmaceutics 1990; 62(2-3): 105-11. 
46. Alex  R,  Bodmeier  R.  Encapsulation  of  water-
soluble  drugs  by  a  modified  solvent  evaporation 
method.  I.  Effect  of  process  and  formulation 
variables  on  drug  entrapment.  Journal  of 
Microencapsulation 1990; 7(3): 347-55. 
47. Xie  J,  Wang  CH.  Self-assembled  biodegradable 
nanoparticles  developed  by  direct  dialysis  for  the 
delivery  of  paclitaxel.  Pharmaceutical  research 
2005; 22(12): 2079-90. 
48. Ceschel  G,  et  al.  Degradation  of  components  in 
drug  formulations:  a  comparison  between  HPLC 
and DSC methods. Journal of pharmaceutical and 
biomedical analysis 2003; 32(4-5): 1067-72. 
49. Jelvehgari  M,  et  al.  Control  of  encapsulation 
efficiency  in  polymeric  microparticle  system  of 
tolmetin.  Pharmaceutical  development  and 
technology 2010; 15(1): 71-9. 
50. Aaltonen,J, et al. Polymorph screening using near-
infrared  spectroscopy.  Analytical  Chemistry  2003; 
75(19): 5267-73. 
51. Gupta  M,  Saini  T.  preformulation  parameters 
characterization  to  design,  development  and 
formulation  of  vancomycin  hydrochloride tablets 
for psudomembranous colitis. international Journal 
of pharmaceutical reaserch and development 2009; 
1(9):1-7. 
52. Jelvehgari M, et al. Preparation and Evaluation of 
Poly  (  -caprolactone)  Nanoparticles-in-
Microparticles  by  W/O/W  Emulsion  Method. 
Iranian  Journal  of  Basic  Medical  Sciences  2010; 
13(3): 1-8. 
53. Capan Y, et al. Preparation and characterization of 
poly(D,L-lactide-co-glycolide)  microspheres  for 
controlled release of human growth hormone. AAPS 
Pharm Sci Tech 2003; 4(2): E28. 
54. Yang  YY,  Chung  TS,  Ping  Ng  N.  Morphology, 
drug  distribution,  and  in  vitro  release  profiles  of  
 56  | 
Loveymi et al. 
 Advanced Pharmaceutical Bulletin, 2012, 2(1), 43-56  Copyright © 2012 by Tabriz University of Medical Sciences 
biodegradable  polymeric  microspheres  containing 
protein  fabricated  by  double-emulsion  solvent 
extraction/evaporation  method.  Biomaterials  2001; 
22(3): 231-41. 
55. Wu JC, et al. Effect of the solvent-non-solvent pairs 
on the surface morphology and release behaviour of 
ethylcellulose  microcapsules  prepared  by  non-
solvent-addition  phase  separation  method.  J 
Microencapsul 1994; 11(3): 297-308. 
56. Wickramasinghe  R,  Liow  JL,  Leong  YK. 
Nanobiotech  congress.  2007;  Available  from: 
http://www.aiche.org/uploadedfiles/SBE/events/Tue
sday07.pdf. 
57. Martin  A,  Bustamante  P,  Chun  AH.  Physical 
Pharmacy  and  Pharmaceutical  Sciences.  Fifth 
edition  ed.  Philadelphia:  Lippincott  Williams  & 
Wilkins, 2006. 
58. Mondal S, et al. Flocculation of yeast suspension by 
a cationic polymer: Characterization of flocculent-
cell  interaction.  2011.  American  Institute  of 
Chemical Engineers. 
59. Mukherjee B,  et  al.  Preparation,  characterization 
and in-vitro evaluation of sustained release protein-
loaded  nanoparticles  based  on  biodegradable 
polymers. Int J Nanomedicine 2008; 3(4): 487-96. 
60. Fonseca C, Simoes S, Gaspar R. Paclitaxel-loaded 
PLGA  nanoparticles:  preparation,  physicochemical 
characterization and in vitro anti-tumoral activity. J 
Control Release 2002; 83(2): 273-86. 
61. Ahlin  P,  et  al.  Investigation  of  polymeric 
nanoparticles  as  carriers  of  enalaprilat  for  oral 
administration. Int J Pharm 2002; 239(1-2): 113-20. 